HIV/AIDS News

DENVER — Long-acting ART was shown to be safe and effective in a study conducted in sub-Saharan Africa — an “essential first step” in demonstrating its potential use to treat HIV on the continent, an expert said.

DENVER — Among people with HIV, hybrid immunity against COVID-19 is more effective at preventing infection and severe disease than vaccination alone, according to a study.

DENVER — People with HIV who have challenges adhering to a daily oral regimen should be offered long-acting formulations of ART, study findings suggest.

DENVER — HIV infections linked to “vampire facials” performed at a spa in New Mexico could have been avoided if the now-closed spa had adhered to appropriate infection prevention and control practices, experts said.

DENVER — Four children born with HIV who initiated ART within 48 hours of delivery later remained in treatment-free remission for over a year after ART was paused, researchers reported.

DENVER — A low weekly dose of semaglutide can safely minimize what used to be called nonalcoholic fatty liver disease in people with HIV, a first-of-its-kind study found.

DENVER — Long-acting injectable ART administered every 8 weeks safely suppresses HIV in adolescents, according to research presented at the Conference on Retroviruses and Opportunistic Infections.

DENVER — Giving patients the option of choosing long-acting PrEP resulted in a fivefold increase in coverage and a reduction in HIV incidence during the SEARCH trial in Uganda, researchers reported.

DENVER — Phase 2 study data showed that a once-weekly oral regimen of an investigational two-drug HIV treatment was well tolerated among patients with HIV and allowed them to maintain viral suppression.

DENVER — The International Antiviral Society-USA (IAS-USA) has updated its HIV treatment guidelines to endorse the off-label use of long-acting injectable ART in patients with HIV viremia.